Follow
Cell dependent cytotoxicity
Antibody-dependent cellular cytotoxicity (ADCC), also known as antibody-dependent cell-mediated cytotoxicity, is a mechanism of the immune response. In ADCC, an effector immune cell lyses (causes it to breakdown) a cell targeted by the immune response. Target cells are identified when immune cells recognize antigens on their surface.
-
OCT 12, 2023 | 8:00 AM
Patient-derived tumoroids, also known as cancer organoids, hold potential as cost-effective models for cancer immunotherapy research. Patient-derived tumor models, which mimic the tumor micr...FEB 23, 2022 | 6:00 AM
Cancer still accounts for nearly 1 in every 4 deaths worldwide. New immunotherapies have the power to induce durable responses in patients with fatal cancers, but only a small percentage of...Speaker: Hans-Dieter Zucht, PhDPresented at: Drug Discovery & Development Virtual Event Series 2022
Sponsored By: Luminex - A DiaSorin CompanyOCT 06, 2021 | 9:00 AM
Background: Localized prostate cancer is notable for tumor heterogeneity, and immune heterogeneity within tumor versus benign areas. B7-H3, a member of the B7 superfamily, is highly expresse...Speaker: Eugene Shenderov, MD, DPhil, FACPPresented at: Cancer Research & Oncology Week Virtual Event Series 2021
Sponsored By: NanoString TechnologiesJUN 02, 2021 | 12:00 AM
Learning Objectives: 1. Define the impact of PD-L1 expressed on non-tumor, non-hematopoietic cells in T cell-mediated tumor control 2. Reveal the contribution of IFNg signaling in dermal lym...SEP 23, 2020 | 8:00 AM
Date: Time: Over the last couple of years, it has become apparent that affinity-tuned CAR T cells display enhanced expansion and prolonged persistence in patients and that this strategy can...SEP 27, 2019 | 9:00 AM
DATE: September 27, 2019TIME: 9:00am PT, 12:00pm ET Thienopyrazole derivatives have recently emerged as effective antitumoral agents with kinase inhibitory activity. In this s...OCT 10, 2018 | 12:00 PM
To date the anatomic extent of tumor (TNM-classification) has been by far the most important factors to predict the prognosis of cancer patients. However, this classification provides limited...Speaker: Jerome Galon, PhDOCT 10, 2018 | 9:00 AM
In prior work, we have pursued how tumor reactive monoclonal antibody (mAb), together with activators of innate immune cells, like NK cells, can augment antibody dependent cell-mediated cytot...Speaker: Paul Sondel, MD, PhDSEP 20, 2018 | 9:00 AM
DATE: September 20 2018TIME: 09:00am PDT, 12:00pm EDT Harnessing the immune system has emerged as a powerful therapeutic strategy in oncology. However, the limited...OCT 11, 2017 | 7:30 AM
The first small molecule inhibitor of the molecular chaperone Heat Shock Protein 90 (HSP90) was identified more than 20 years ago. Upon determination of the drug binding site and clarificatio...OCT 16, 2013 | 7:00 AMC.E. CREDITS
The adjuvant therapy of choice for superficial bladder cancer is the intravesical instillation of live Mycobacterium bovis Bacillus Calmette-Guerin (BCG). In spite of the fact that this thera...Speaker: R. Claudio Aguilar, PhD
OCT 12, 2023 | 8:00 AM
Patient-derived tumoroids, also known as cancer organoids, hold potential as cost-effective models for cancer immunotherapy research. Patient-derived tumor models, which mimic the tumor micr...
FEB 23, 2022 | 6:00 AM
Cancer still accounts for nearly 1 in every 4 deaths worldwide. New immunotherapies have the power to induce durable responses in patients with fatal cancers, but only a small percentage of...
Speaker:
Hans-Dieter Zucht, PhD
Presented at: Drug Discovery & Development Virtual Event Series 2022
Sponsored By: Luminex - A DiaSorin Company
Sponsored By: Luminex - A DiaSorin Company
OCT 06, 2021 | 9:00 AM
Background: Localized prostate cancer is notable for tumor heterogeneity, and immune heterogeneity within tumor versus benign areas. B7-H3, a member of the B7 superfamily, is highly expresse...
Speaker:
Eugene Shenderov, MD, DPhil, FACP
Presented at: Cancer Research & Oncology Week Virtual Event Series 2021
Sponsored By: NanoString Technologies
Sponsored By: NanoString Technologies
JUN 02, 2021 | 12:00 AM
Learning Objectives: 1. Define the impact of PD-L1 expressed on non-tumor, non-hematopoietic cells in T cell-mediated tumor control 2. Reveal the contribution of IFNg signaling in dermal lym...
SEP 23, 2020 | 8:00 AM
Date: Time: Over the last couple of years, it has become apparent that affinity-tuned CAR T cells display enhanced expansion and prolonged persistence in patients and that this strategy can...
SEP 27, 2019 | 9:00 AM
DATE: September 27, 2019TIME: 9:00am PT, 12:00pm ET Thienopyrazole derivatives have recently emerged as effective antitumoral agents with kinase inhibitory activity. In this s...
OCT 10, 2018 | 12:00 PM
To date the anatomic extent of tumor (TNM-classification) has been by far the most important factors to predict the prognosis of cancer patients. However, this classification provides limited...
Speaker:
Jerome Galon, PhD
OCT 10, 2018 | 9:00 AM
In prior work, we have pursued how tumor reactive monoclonal antibody (mAb), together with activators of innate immune cells, like NK cells, can augment antibody dependent cell-mediated cytot...
Speaker:
Paul Sondel, MD, PhD
SEP 20, 2018 | 9:00 AM
DATE: September 20 2018TIME: 09:00am PDT, 12:00pm EDT Harnessing the immune system has emerged as a powerful therapeutic strategy in oncology. However, the limited...
OCT 11, 2017 | 7:30 AM
The first small molecule inhibitor of the molecular chaperone Heat Shock Protein 90 (HSP90) was identified more than 20 years ago. Upon determination of the drug binding site and clarificatio...
OCT 16, 2013 | 7:00 AM
C.E. CREDITS
The adjuvant therapy of choice for superficial bladder cancer is the intravesical instillation of live Mycobacterium bovis Bacillus Calmette-Guerin (BCG). In spite of the fact that this thera...
Speaker:
R. Claudio Aguilar, PhD